A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Issue 1 (6th March 2017)

• Record Type: Journal Article
• Authors: Mo, Yi; Stromswold, Julie; Wilson, Kimberly; Holder, Daniel; Sur, Cyrille; Laterza, Omar; Savage, Mary J.; Struyk, Arie; Scheltens, Philip; Teunissen, Charlotte E.; Burke, James; Macaulay, S. Lance; Bråthen, Geir; Sando, Sigrid Botne; White, Linda R.; Weiss, Christy; Cowes, Arturo; Bush, Michele M.; DeSilva, Ganga; Darby, David G.; Rainey‐Smith, Stephanie R.; Surls, Jackie; Sagini, Eileen; Tanen, Michael; Altman, Amy; Luthman, Johan; Egan, Michael F.
• Is Part Of: Alzheimer's & dementia. Volume 6:Issue 1(2017)
• Page Start: 201
• Page End: 209
• Publication Date: 2017-03-06
• Subjects: Alzheimer's disease -- Diagnostic test assessment -- PET -- Amyloid β42 -- Tau; Alzheimer's disease -- Periodicals; Alzheimer's disease -- Diagnosis -- Periodicals; Dementia -- Periodicals; Dementia -- Diagnosis -- Periodicals; 616.831
• DOI: 10.1016/j.dadm.2017.02.004
• Languages: English
• ISSNs: 2352-8729

Abstract

Abstract: Introduction: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild‐to‐moderate Alzheimer's disease (AD) subjects from healthy elderly control (HC) subjects. Methods: A CSF tau/Aβ42 cutoff criteria was chosen, which distinguished the groups and maximized concordance with amyloid PET. Performance was assessed using an independent validation cohort. Results: A tau/Aβ42 = 0.215 cutoff provided 94.8% sensitivity and 77.7% specificity. Concordance with PET visual reads was estimated at 86.9% in a ∼50% PET positive population. In the validation cohort, the cutoff demonstrated 78.4% sensitivity and 84.9% specificity to distinguish the AD and HC populations. Discussion: A tau/Aβ42 cutoff with acceptable sensitivity and specificity distinguished HC from mild‐to‐moderate AD subjects and maximized concordance to brain amyloidosis. The defined cutoff demonstrated that CSF analysis may be useful as a surrogate to imaging assessment of AD pathology.